← back to search

Rasmus O. Bak

Aarhus University · DK
Area of research
Molecular Biology · Genetics
Research interest
Research interests include CRISPR and Genetic Engineering, Virus-based gene therapy research, RNA Interference and Gene Delivery, and CAR-T cell therapy research.
h-index
38
citations
8,513
works
132
NIH funding
primary concept
email

Recent publications

Single-stranded HDR templates with truncated Cas12a-binding sequences improve knock-in efficiencies in primary human T cells
Molecular Therapy — Nucleic Acids 2025cited by 6position: middledoi
CD5 expression by dendritic cells directs T cell immunity and sustains immunotherapy responses
Science 2023cited by 112position: middledoi
Combined lineage tracing and scRNA-seq reveals unexpected first heart field predominance of human iPSC differentiation
eLife 2023cited by 48position: middledoi
Abstract 14922: Combined Lineage Tracing and Scrna-Seq Reveals Unexpected First Heart Field Predominance of Human Ipsc Differentiation
Circulation 2022cited by 0position: middledoi
Abstract 12385: TBX5-Based Lineage Tracing Identifies a Propensity for Left Ventricular Cardiomyocyte Differentiation of Human Induced Pluripotent Stem Cells Using Biphasic Modulation of WNT Signaling
Circulation 2021cited by 0position: middledoi
STEEP mediates STING ER exit and activation of signaling
Nature Immunology 2020cited by 172position: middledoi
Author Correction: STEEP mediates STING ER exit and activation of signaling
Nature Immunology 2020cited by 8position: middledoi
Priming Human Hematopoietic Stem and Progenitor Cells for Cas9/Sgrna and rAAV6-Mediated Homologous Recombination
Blood 2017cited by 0position: middledoi
Activation of proto-oncogenes by disruption of chromosome neighborhoods
Science 2016cited by 1,108position: middledoi
Influenza A virus targets a cGAS-independent STING pathway that controls enveloped RNA viruses
Nature Communications 2016cited by 225position: middledoi
39. FACS-Based Enrichment of a Highly Purified HBB-Targeted Hematopoietic Stem and Progenitor Cell Population Using rAAV6 and CRISPR/Cas9
Molecular Therapy 2016cited by 0position: middledoi
Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells
Nature Biotechnology 2015cited by 1,120position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Matthew H. Porteus · Stanford University7 papers (2015–2023)Sharon L. Paige · Palo Alto University3 papers (2021–2023)Sean M. Wu · Cardiovascular Institute of the South3 papers (2021–2023) · 3 papers (2021–2023) · 3 papers (2021–2023) · 3 papers (2021–2023)Soah Lee · California Institute for Regenerative Medicine3 papers (2021–2023)William R. Goodyer · Cardiovascular Institute of the South3 papers (2021–2023)Francisco X. Galdos · Stanford University3 papers (2021–2023)Adrija Darsha · Baylor Scott & White Medical Center - Temple2 papers (2022–2023)Daniel P. Dever · Palo Alto University2 papers (2016–2017)Ayal Hendel · Gladstone Institutes2 papers (2015–2016)Alec B. Wilkens · Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa2 papers (2015–2016)Joab Camarena · Palo Alto University2 papers (2016–2017) · 2 papers (2022–2023)Andreas Reinisch · Palo Alto University1 papers (2016–2016)Denes Hnisz · Max Planck Institute for Molecular Genetics1 papers (2016–2016)Job Dekker · Howard Hughes Medical Institute1 papers (2016–2016)Shervin Bahrami · Aarhus University1 papers (2016–2016)M. Kyle Cromer · Gladstone Institutes1 papers (2017–2017)